What is CJC-1295 + Ipamorelin? A GH Secretagogue Breakdown
Compound Spotlight
CJC-1295 and Ipamorelin are two of the most frequently paired compounds in growth hormone secretagogue research, each acting on a different receptor pathway to studied effect.
Quick summary
- Combines two compounds acting on separate receptors: CJC-1295 (GHRH receptor) and Ipamorelin (ghrelin receptor).
- Studied for growth hormone release, body composition, and recovery research.
- Ipamorelin is noted in research for comparatively low cortisol and prolactin effects vs. older secretagogues.
- Frequently paired to study whether two receptor pathways together amplify natural GH pulsatility.
What is CJC-1295 + Ipamorelin?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), studied for its ability to stimulate the pituitary gland to release growth hormone. Ipamorelin is a separate class of compound, a growth hormone secretagogue that acts on the ghrelin receptor. Because they act on different receptors, researchers frequently study them in combination.
What it is studied for
- Growth hormone release pathway research
- Body composition and recovery research
- Sleep quality studies related to growth hormone pulsatility
- Combined receptor-pathway research (GHRH receptor and ghrelin receptor)
How it is thought to work
CJC-1295 works on the GHRH receptor, extending the natural pulse of growth hormone release from the pituitary gland. Ipamorelin works separately on the ghrelin receptor, triggering an additional, more selective pulse of growth hormone with comparatively little effect on cortisol or prolactin compared to older-generation secretagogues. Studying the two together is intended to amplify the natural release pattern through two distinct receptor pathways rather than one.
Research history
CJC-1295 was developed as a longer-acting analog of growth hormone-releasing hormone, designed to extend the natural pulse of GH release beyond what native GHRH allows. Ipamorelin was developed separately as part of a class of ghrelin receptor agonists researched for a more selective growth hormone release profile than earlier secretagogues like GHRP-6, which were associated with more pronounced cortisol and prolactin effects.
As research on growth hormone secretagogues matured, combining a GHRH analog with a ghrelin receptor agonist became a common research approach, based on the premise that stimulating two separate, non-competing receptor pathways produces a more pronounced pulse than either compound alone.
Our CJC-1295 + Ipamorelin
Every lot we sell is sent to an independent, third-party lab before it is listed, and the resulting Certificate of Analysis is published for that exact lot, confirming identity and purity.
For laboratory and research use only. Not for human consumption. This article is for informational purposes and summarizes existing published research; it is not medical advice.
Frequently asked questions
Why are CJC-1295 and Ipamorelin studied together?
They act on two separate receptor pathways involved in growth hormone release, the GHRH receptor and the ghrelin receptor. Researchers study the combination to look at whether the two pathways produce an amplified effect together.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab, confirming both identity and purity. You can look up any lot number directly on our site.
